首页> 外文期刊>Diagnostic cytopathology >Cytological criteria to predict basal phenotype of breast carcinomas.
【24h】

Cytological criteria to predict basal phenotype of breast carcinomas.

机译:预测乳腺癌基础表型的细胞学标准。

获取原文
获取原文并翻译 | 示例
           

摘要

Breast carcinoma is a heterogeneous disease. It can be classified into phenotypes based on the expression of certain proteins, with distinct differences in prognosis. The basal phenotype is associated with worse prognosis and it still remains without specific treatment. However, there is currently no international consensus on the cytological criteria that could predict this phenotype. The purpose of the study was to evaluate the cytological criteria in fine-needle aspiration biopsy and to identify their association with the basal phenotype of breast carcinoma. Fine-needle aspiration biopsy specimens and tissue sections (mastectomy specimen) from 74 cases of high-grade invasive ductal breast carcinomas were consecutively retrieved from the files of three institutions. Breast carcinomas were studied using the tissue microarray technique, being classified into phenotypes: luminal A, luminal B, HER2 overexpression, and basal. The cytological criteria for all cases were reviewed blindly by two pathologists according to five cytological criteria: cellularity, cell pattern, presence of necrosis, nucleoli, and nuclear atypia. Exact Fisher test was used to test the association between cytological criteria and the phenotypes of breast carcinoma. Necrosis was present in 64.7% of basal breast carcinomas, and 31.1% of nonbasal breast carcinomas, and that result was statistically significant, showing an odds ratio (OR) of 3.80. The basal phenotype, compared with the luminal A, showed more necrosis (OR = 6.97), present/prominent nucleoli (OR = 8.18), and cellularity more frequently (OR = 18.03). Necrosis, as well as present/prominent nucleoli and abundant cellularity are criteria more frequently associated to the basal phenotype of breast carcinoma.
机译:乳腺癌是一种异质性疾病。可以根据某些蛋白质的表达将其分类为表型,在预后方面存在明显差异。基础表型与预后较差有关,并且仍需进一步治疗。但是,目前尚无关于可预测该表型的细胞学标准的国际共识。这项研究的目的是评估细针穿刺活检中的细胞学标准,并确定它们与乳腺癌的基础表型的关系。从三个机构的档案中连续检索了74例高度浸润性导管癌的细针穿刺活检标本和组织切片(乳房切除术标本)。使用组织微阵列技术研究了乳腺癌,将其分为表型:腔A,腔B,HER2过表达和基底型。两名病理学家根据五种细胞学标准对所有病例的细胞学标准进行了盲目审查:细胞性,细胞模式,坏死的存在,核仁和核型异型。精确的Fisher检验用于检验细胞学标准与乳腺癌表型之间的关联。坏死在基础乳腺癌中占64.7%,在非基础乳腺癌中占31.1%,该结果具有统计学意义,比值比(OR)为3.80。与管腔A相比,基础表型显示出更多的坏死(OR = 6.97),存在/突出的核仁(OR = 8.18)和细胞增多(OR = 18.03)。坏死,以及当前/突出的核仁和丰富的细胞性是与乳腺癌的基础表型更经常相关的标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号